Skip to main content

Transplantation Infection

4
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
2
EverolimusPhase 41 trial
EverolimusPhase 41 trial
Everolimus 0.25 and 0.75 mg tabletsPhase 31 trial
Active Trials
NCT01276457Completed223Est. Feb 2009
NCT02328963Completed186Est. Oct 2018
NCT02084446Completed120Est. Jul 2017
ADMA Biologics
ADMA BiologicsNJ - Ramsey
1 program
1
Hepatitis C Immune Globulin Intravenous (Human)Phase 21 trial
Active Trials
NCT00473824Terminated7Est. Feb 2009
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
immunization appN/A1 trial
Active Trials
NCT04336735Unknown45Est. Aug 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozEverolimus
SandozEverolimus
SandozEverolimus 0.25 and 0.75 mg tablets
ADMA BiologicsHepatitis C Immune Globulin Intravenous (Human)
Colorado Therapeuticsimmunization app

Clinical Trials (5)

Total enrollment: 581 patients across 5 trials

NCT02328963SandozEverolimus

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

Start: May 2014Est. completion: Oct 2018186 patients
Phase 4Completed
NCT02084446SandozEverolimus

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Start: Dec 2012Est. completion: Jul 2017120 patients
Phase 4Completed
NCT01276457SandozEverolimus 0.25 and 0.75 mg tablets

Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients

Start: May 2006Est. completion: Feb 2009223 patients
Phase 3Completed
NCT00473824ADMA BiologicsHepatitis C Immune Globulin Intravenous (Human)

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

Start: May 2007Est. completion: Feb 20097 patients
Phase 2Terminated
NCT04336735Colorado Therapeuticsimmunization app

Improving Immunization Rates in Transplant Candidates Through the Use of a Health Information Technology Tool

Start: Jan 2022Est. completion: Aug 202445 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.